Kathleen M. Gavin
Matthew L. Sundermann
Alethea WielandA Correction on
Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings
by Gavin KM, Sundermann ML and Wieland A (2025). Front. Drug Saf. Regul. 5:1626822. doi: 10.3389/fdsfr.2025.1626822
The reference for [EMA, 2017] was erroneously written as “EMA (2017). Guideline on good pharmacovigilance practices (GVP) module IX–Signal management. Available online at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf.” It should be “European Medicines Agency (2017). Guideline on good pharmacovigilance practices (GVP) module IX–Signal management. Available online at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf”.
The reference for European Medicines Society, 2023 was erroneously written as “European Medicines Society (2023). ICH M14 general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines - scientific guideline. Available online at: https://www.ema.europa.eu/en/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines-scientific-guideline”. It should be “European Medicines Agency (2025). ICH M14 general principles on plan, design and analysis of pharmacoepidemiological studies that utilize real-world data for safety assessment of medicines - scientific guideline. Available online at: https://www.ema.europa.eu/en/ich-m14-guideline-general-principles-plan-design-analysis-pharmacoepidemiological-studies-utilize-real-world-data-safety-assessment-medicines-scientific-guideline”.
The reference for European Medicines Society, 2025 was erroneously written as “European Medicines Society (2025). Data analysis and real world interrogation network (DARWIN EU). Available online at: https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence/data-analysis-real-world-interrogation-network-darwin-eu”. It should be “European Medicines Agency (2025). Data analysis and real world interrogation network (DARWIN EU). Available online at: https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/real-world-evidence/data-analysis-real-world-interrogation-network-darwin-eu”.
The reference for Rosati et al., 2022 was erroneously written as “Rosati, K., Jorgensen, N., Soliz, M., and Evans, B. (2022). HIPAA and common rule compliance in the Sentinel initiative. Sentinel initiative principles and policies”. It should be “Rosati, K., Jorgensen, N., Soliz, M., and Evans, B. (2018). HIPAA and common rule compliance in the Sentinel initiative. Sentinel initiative principles and policies. Available at: https://www.sentinelinitiative.org/sites/default/files/communications/publications-presentations/HIPAA-Common-Rule-Compliance-in-Sentinel-Initiative.pdf”.
The reference for U.S. Food and Drug Administration, 2023a was erroneously written as “U.S. Food and Drug Administration (2023a). Data standards for drug and biological product submissions containing real-world data guidance document. Available online at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug”. It should be “U.S. Food and Drug Administration (2023a). Data standards for drug and biological product submissions containing real-world data guidance document. Available online at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-drug-and-biological-product-submissions-containing-real-world-data”.
The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: real world data, safety surveillance, pharmacovigilance, risk management, privacy preserving record linkage (PPRL), tokenization, data linkage, federated data sharing
Citation: Gavin KM, Sundermann ML and Wieland A (2025) Correction: Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings. Front. Drug Saf. Regul. 5:1729828. doi: 10.3389/fdsfr.2025.1729828
Received: 21 October 2025; Accepted: 22 October 2025;
Published: 07 November 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Gavin, Sundermann and Wieland. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kathleen M. Gavin, a2F0aGxlZW5AZGF0YXZhbnQuY29t